Glossary

Biosimilar

A biologic medicine shown to be highly similar to an FDA-approved biologic, with no meaningful difference in safety or effect, often sold at a lower price.

Also called: biosimilar drug, biosimilar product, follow-on biologic

Biologic drugs are made from living cells, such as the antibodies and proteins used for arthritis, cancer and diabetes. Because they cannot be copied molecule for molecule the way a pill can, a follow-on version is called a biosimilar, not a generic drug. The FDA approves it only after it is shown to be highly similar to the original, called the reference product, with no clinically meaningful differences in safety or effectiveness.

Some biosimilars also get an "interchangeable" designation from the FDA, which lets a pharmacist substitute them for the reference product where state law allows. Others require a new prescription.

Biosimilars matter because many biologics are expensive specialty drug products. Plans often prefer a biosimilar on the formulary and may require you to try it before covering the original. As a labeled hypothetical, if a plan charges 30% on the top tier and a biosimilar's allowed amount is $2,000 instead of $3,000, your share per fill falls from $900 to $600.

The common mistake is expecting a biosimilar to be a generic with a pharmacy-counter price. Ask your plan which version it covers.

Last reviewed November 16, 2026

In the index now

Related terms

Related blog